Management of Large Immature Ovarian Teratoma with Coexisting Mucinous Cystadenoma

Surgical Management

Perform a fertility‑preserving unilateral salpingo‑oophorectomy (USO) as the standard primary operation for a large immature teratoma, ensuring complete tumor removal while maintaining reproductive potential. 1
Conduct comprehensive surgical staging for all cases, which must include:
Lymphadenectomy is not routinely performed for ovarian germ‑cell tumors; it should be reserved for nodes that appear clinically abnormal. 2
Preserve the contralateral ovary and the uterus even when the disease seems advanced, because these tumors are highly chemosensitive. 1

Stage IA, Grade 1 immature teratoma: No adjuvant chemotherapy is required after adequate staging; patients proceed directly to surveillance. 1
Stage IA‑IC, Grade 2‑3 immature teratoma: Adjuvant chemotherapy is recommended. Relapse risk ranges from 2‑20 % for Grade 2 and 20‑40 % for Grade 3 disease. 2
The standard chemotherapy regimen is BEP (Bleomycin, Etoposide, Cisplatin) administered over a 5‑day cycle:

Year 1:
Years 2‑10: Gradually extend the intervals between clinical visits, imaging, and laboratory tests as the patient remains disease‑free. 2

Avoid postponing postoperative chemotherapy; surgical recovery should be managed to permit timely initiation of systemic therapy. 1
Recognize the risk of growing‑teratoma syndrome: any resectable residual mass after chemotherapy should be surgically removed, especially when tumor markers have normalized. 3

Systematically monitor for late effects of BEP chemotherapy, including pulmonary dysfunction, peripheral neuropathy, ototoxicity, cardiovascular disease, and gonadal dysfunction. 2

When appropriately staged and treated, Stage I immature teratoma achieves approximately 90 % long‑term disease‑free survival; the coexistent mucinous cystadenoma does not adversely affect outcome. 2